Home › Core › ISCC-IDs › 28C93N1tKcgnB

View ISCC-ID

Core Data

28C93N1tKcgnB
ISCC-ID - digital asset identifier
CCNGJMeFfQVnP-CTL2PLrFbaBey-CD54vboAoqqxo-CRfsMsCpn71sF
ISCC-CODE - digital asset descriptor
2QTa5N4aeSrCB2MLoPdPF4AsTjstJgcLTnd
PUBLIC-KEY or WALLET-ADDRESS of DECLARING PARTY
0
Number of times updated

Seed Metadata (Immutable)

efficacy of certolizumab pegol with and without concomitant use of diseasemodifying antirheumatic drugs over 4 years in psoriati

Ledger Reference

coblo
Source Ledger/Blockchain
12400089
N-th ISCC Decleration on source ledger
6bdbc924a151d69d8036cac547e201f780ffd13bc2179fc096045f48aea1d653
Hash of block that includes the ISCC-DECLARATION
55cc7b564136381ccf9414122f0cba99f7c9f2f9d34354ebd4f35dd7527ef93a
Hash of transaction that includes the ISCC-DECLERATION
0
Output index that includes ISCC-DECLERATION (UTXO based chains)

Mutable Metadata

[{"data": {"name": "Efficacy of certolizumab pegol with and without concomitant use of disease-modifying anti-rheumatic drugs over 4\u00a0years in psoriatic arthritis patients: results from the RAPID-PsA randomized controlled trial", "@type": "ScholarlyArticle", "genre": "journal-article", "author": [{"name": "J. A. Walsh", "@type": "Person"}, {"name": "A. B. Gottlieb", "@type": "Person"}, {"name": "B. Hoepken", "@type": "Person"}, {"name": "T. Nurminen", "@type": "Person"}, {"name": "P. J. Mease", "@type": "Person"}], "license": "cc-by", "@context": "http://schema.org/", "encoding": [{"@type": "MediaObject", "contentUrl": "https://link.springer.com/content/pdf/10.1007%2Fs10067-018-4227-7.pdf", "encodingFormat": "application/pdf"}], "publisher": {"name": "Springer Science and Business Media LLC", "@type": "Organization"}, "identifier": [{"@type": "PropertyValue", "value": "10.1007/s10067-018-4227-7", "propertyID": "DOI"}, {"@type": "PropertyValue", "value": "CCNGJMeFfQVnP-CTL2PLrFbaBey-CD54vboAoqqxo-CRfsMsCpn71sF", "propertyID": "ISCC"}], "datePublished": "2018-09-06"}, "schema": "schema.org", "mediatype": "application/ld+json"}]
Close